Prevalence of HIV-1 transmitted drug resistance and its impact on the effectiveness of antiretroviral therapy - Minas Gerais state, Brazil / Prevalência de resistência transmitida do HIV-1 e seu impacto na efetividade da terapia antirretroviral – Minas Gerais, Brasil
DOI:
https://doi.org/10.34119/bjhrv5n1-090Keywords:
HIV-1, effectiveness, antiretroviral therapy, transmitted drug resistance.Abstract
The transmission and occurrence of resistance associated mutations (RAMs) are among the challenges for a successful HIV Treatment. Therefore, continuous HIV drug resistance surveillance of prevalence and incidence is recommended. The objective this study was to analyze the prevalence and impact of transmitted drug resistance (TDR) on the first-line ART effectiveness. This is a retrospective observational study that evaluated HIV-1-infected treatment-naïve individuals with pre-antiretroviral therapy (ART) genotype resistance test results, between 2014 and 2015, in Minas Gerais state’s, Brazil. The ART effectiveness was compared in individual with and without TDR, considering viral load (VL) <50 copies/mL at the 12 and 24-month endpoint. Reverse transcriptase and protease sequences were genotyped by Sanger sequencing. A total of 170 individuals were selected. HIV-1 subtype B was highly prevalent (63.5%) and prevalence of TDR was 14.1%. That included 62.5% RAMs associated with non-nucleoside reverse-transcriptase inhibitors (NNRTIs), 29.2% with nucleos(t)ide transcriptase inhibitors (NRTIs) and 25% with protease inhibitors (PIs). The overall ART effectiveness measured at 12 and 24 months was, respectively: 91.0% and 93.4% between individuals without TDR; 88.2% and 93.3% in individuals with TDR. Among the individuals starting first-line ART with less than three active drugs (16/24), seven individuals achieved VL <50 copies/mL in the presence of K103N mutation and receiving efavirenz-containing ART. Moderate prevalence of TDR was observed in this study, although observed that some NNRTI TDR, did not impact on the effectiveness of efavirenz-based regimens, without major differences on the effectiveness of first-line ART between the groups with or without TDR.
References
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Relatório de Monitoramento Clínico do HIV 2020. 2020;99. Available from: http://www.aids.gov.br/pt-br/pub/2020/relatorio-de-monitoramento-clinico-do-hiv-2020
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Doenças de Condições Crônicas e Infecções Sexualmente Transmissíveis. Boletim Epidemiológico HIV / Aids | 2020. 2020;1:68. Available from: http://www.aids.gov.br/pt-br/pub/2020/boletim-epidemiologico-hivaids-2020
WHO. Hiv Drug Resistance Report 2017 Trends Quality Action [Internet]. Geneva, Switzerland: World Health Organization. 2017. p. 82. Available from: https://apps.who.int/iris/bitstream/handle/10665/255896/9789241512831-eng.pdf
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de DST, AIDS e Hepatites Virais. Protocolo Clínico e diretrizes terapêutica para manejo da infecção pelo hiv em adultos. 2018. 412 p.
Ho ZJM, Huang F, Wong CS, Chua L, Ma S, Chen MI, et al. Using a HIV registry to develop accurate estimates for the HIV care cascade – the Singapore experience. J Int AIDS Soc. 2019;22(7):10.1002/jia2.25356.
Louis FJ, Buteau J, François K, Hulland E, Domerçant JW, Yang C, et al. Virologic outcome among patients receiving antiretroviral therapy at five hospitals in Haiti. PLoS One. 2018;13(1):1–12.
Mendicino CCP, Silva GJ da, Braga LP, Colosimo EA, Guimarães MDC, Pádua CAM de. Monitoring HIV infection in Minas Gerais state: 15-year assessment of adults living with HIV initiating Antiretroviral Therapy. Rev Soc Bras Med Trop. 2020;53(July):e20200360.
Bahls LD, Canezin PH, Reiche EMV, Fernandez JCC, Dias JRC, Meneguetti VAF, et al. Moderate prevalence of HIV‑1 transmitted drug resistance mutations in southern Brazil. AIDS Res Ther [Internet]. 2019;16(4):1–7. Available from: https://doi.org/10.1186/s12981-019-0219-1
Rusine J, Asiimwe-Kateera B, van de Wijgert J, Boer KR, Mukantwali E, Karita E, et al. Low Primary and Secondary HIV Drug-Resistance after 12 Months of Antiretroviral Therapy in Human Immune-Deficiency Virus Type 1 (HIV-1)-Infected Individuals from Kigali, Rwanda. PLoS One. 2013;8(8).
Tang MW, Shafer RW. HIV-1 antiretroviral resistance: Scientific principles and clinical applications. Drugs. 2012;72(9):1–25.
Taylor BS, Olender SA, Tieu H-V, Wilkin TJ. CROI 2016 : Advances in Antiretroviral Therapy. Top Antivir Med. 2016;24(1):59–81.
Kyeyune F, Gibson RM, Nankya I, Venner C, Metha S, Akao J, et al. Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure. Antimicrob Agents Chemother. 2016;60(6):3380–97.
Duani H, Aleixo AW, Tupinambás U. Trends and predictors of HIV-1 acquired drug resistance in Minas Gerais , Brazil : 2002 – 2012. Brazilian J Infect Dis. 2017;21(2):148–54.
Hofstra LM, Rivas ES, Nijhuis M, Bank LEA, Wilkinson E, Kelly K, et al. High rates of transmission of drug-resistant HIV in Aruba resulting in reduced susceptibility to the WHO recommended first-line regimen in nearly half of newly diagnosed HIV-infected patients. Clin Infect Dis. 2017;64(8):1092–7.
Taniguchi T, Nurutdinova D, Grubb JR, Onen NF, Shacham E, Donovan M, et al. Transmitted drug-resistant HIV type 1 remains prevalent and impacts virologic outcomes despite genotype-guided antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28(3):259–64.
WHO. Technical report HIV drug resistance 2021. Geneva, Switz World Heal Organ [Internet]. 2021;(November):125. Available from: https://www.who.int/publications/i/item/9789240038608
WHO. HIV Drug Resistance Report [Internet]. 2019. 27 p. Available from: http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Who+hiv+drug+resistance+report+2012#5
Venter W, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different produgs of tenofovir to treat HIV. New Engl Jounal Med. 2019;381(9):803–15.
Walmsley S, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutieŕrez F, et al. Dolutegravir plus Abacavir-Lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–18.
Pinto Neto LF da S, Perini F de B, Aragón MG, Freitas MA, Miranda AE. Protocolo Brasileiro para Infecções Sexualmente Transmissíveis 2020: infecção pelo HIV em adolescentes e adultos. Epidemiol e Serviços Saúde. 2021;30(spe1):1–13.
Bennett D, Camacho R, Otelea D, Kuritzkes D, H F, M K, et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance : 2009 Update. PLoS One. 2009;4(3):e4724.
Tavares M de PM, Souza RF de, Tavares A de PM, Vilela MF de C, Souza VF de, Fontana AP, et al. Epidemiological profile of AIDS and HIV infection in Brazil: Bibliographical review. Brazilian J Heal Rev. 2021;4(1):786–90.
Freitas AN de, Pereira BGR, Mesquita CEB de, Patrício D da S, Borges LC, Almeida MR de, et al. Analysis of HIV cases registered in the brazilian scenario. Brazilian J Heal Rev. 2020;3(4):10054–69.
WHO. WHO HIV Drug Resistance Report 2012. 2012;84. Available from: http://apps.who.int/iris/bitstream/10665/75183/1/9789241503938_eng.pdf
Alencar CS, Sabino EC, Carvalho SMF, Leao SC, Carneiro-Proietti AB, Capuani L, et al. HIV genotypes and primary drug resistance among HIV seropositive blood donors in Brazil: role of infected blood donors as sentinel populations for molecular surveillance of HIV. J Acquir Immune Defic Syndr. 2013;63(3):387–92.
Tupinambás U, Duani H, Martins AVC, Aleixo AW, Greco DB. Transmitted human immunodeficiency virus-1 drug resistance in a cohort of men who have sex with men in Belo Horizonte , Brazil - 1996-2012. Mem Inst Oswaldo Cruz. 2013;108(4):470–5.
Arruda M, Boullosa L, Cardoso C, da Costa C, Alves C, de Lima S, et al. Brazilian network for HIV Drug Resistance Surveillance ( HIV-BresNet ): a survey of treatment-naive individuals. J Int AIDS Soc. 2018;21(3):1–8.
Ferreira A, Coelho L, Grinsztejna E, Jesus C, Guimarães M, Veloso V, et al. Transmitted drug resistance in patients with acute / recent HIV infection in Brazil. Brazilian J Infect Dis [Internet]. 2017;21(4):396–401. Available from: http://dx.doi.org/10.1016/j.bjid.2017.03.013
Gagliani LH, Alkmim Maia WT, Sá-Filho D, Janini LM, Sucupira MC, Caseiro MM, et al. The Association Between Primary Antiretroviral Resistance and HAART Virologic Failure in a Developing Set. AIDS Res Hum Retroviruses [Internet]. 2011;27(3):251–6. Available from: http://www.liebertonline.com/doi/abs/10.1089/aid.2010.0150
Westin MR, Biscione FM, Fonseca M, Ordones M, Rodrigues M, Greco DB, et al. Resistance-Associated Mutation Prevalence According to Subtypes B and Non-B of HIV Type 1 in Antiretroviral-Experienced Patients in Minas Gerais, Brazil. AIDS Res Hum Retroviruses [Internet]. 2011;27(9):981–7. Available from: http://www.liebertonline.com/doi/abs/10.1089/aid.2010.0260
Ferreira F, Pinto J, Kakehasi F, Cleto S, Tupinambas U, Aleixo AW, et al. Prevalence of Primary Drug Resistance-Associated Mutations Among HIV Type 1 Vertically Infected Children in Belo Horizonte , Brazil. AIDS Res Hum Retroviruses. 2010;26(2):229–32.
Couto-Fernandez JC, Silva-de-Jesus C, Veloso VG, Rachid M, Gracie RSG, Chequer-Fernandez SL, et al. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy. Mem Inst Oswaldo Cruz [Internet]. 2005;100(1):73–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15867968
Ferreira J, Rodrigues R, Lança A, Almeida V, Rocha S, Ragazzo T, et al. Transmitted drug resistance among people living with HIV/aids at major cities of Sao Paulo State, Brazil. Adv Virol. 2013;1–7.
Struck D, Roman F, De Landtsheer S, Servais J-Y, Lambert C, Masquelier C, et al. Near Full-Length Characterization and Population Dynamics of the Human Immunodeficiency Virus Type I Circulating Recombinant Form 42 (CRF42_BF) in Luxembourg. AIDS Res Hum Retroviruses [Internet]. 2015;31(5):554–8. Available from: http://online.liebertpub.com/doi/10.1089/aid.2014.0364
Saladini F, Foley BT, Rosi A, Vicenti I, Nannetti G, Meini G, et al. Near full-length sequence analysis of HIV type 1 BF recombinants from Italy. AIDS Res Hum Retroviruses. 2012;28(3):299–303.
Santoro MM, Perno CF. HIV-1 Genetic Variability and Clinical Implications. ISRN Microbiol [Internet]. 2013;2013:1–20. Available from: https://www.hindawi.com/archive/2013/481314/
De Andrade SD, Sabidó M, Monteiro WM, Benzaken AS, Tanuri A. Drug resistance in antiretroviral-naive children newly diagnosed with HIV-1 in Manaus, Amazonas. J Antimicrob Chemother. 2017;72(6):1774–83.
Guimaraes PMDS, Ferreira JLDP, Coelho LPO, Cavalcanti JDS, Lopes GISL, Matsuda EM, et al. Transmitted Drug Resistance among Recently Diagnosed Adults and Children in Sao Paulo, Brazil. AIDS Res Hum Retroviruses. 2015;31(12):1219–24.
Avila-Rios S, Sued O, Rhee S, Shafer RW, Reyes- G. Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean : A Systematic Review and Meta- Analysis. PLoS One. 2016;1–36.
Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Giguel F, Iii WAM, et al. Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure. J Infect Dis. 2010;201(5):662–71.
Delobel P, Saliou A, Nicot F, Dubois M, Trancart S, Tangre P, et al. Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS One. 2011;6(6):21–3.
Derache A, Iwuji CC, Baisley K, Danaviah S, Marcelin A-G, Calvez V, et al. Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249. Clin Infect Dis. 2019;69(2):207–14.
Beck IA, Levine M, McGrath CJ, Bii S, Milne RS, Kingoo JM, et al. Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya. EClinicalMedicine. 2020;18.
Cardoso SW, Luz PM, Velasque L, Torres T, Coelho L, Freedberg KA, et al. Effectiveness of first-line antiretroviral therapy in the IPEC cohort , Rio de Janeiro , Brazil. AIDS Res Ther. 2014;11(1):1–10.
Costa JDO, Cecatto M das GB, Silveira MR, Bonolo P de F, Reis EA, Acurcio F de A. Efetividade da terapia antirretroviral na era de medicamentos em dose fixa combinada. Rev Saude Publica. 2018;52(87):1–13.
Meireles MV, Pascom ARP, Duarte EC, Mcfarland W. Comparative effectiveness of first-line antiretroviral therapy : results from a large real-world cohort after the implementation of dolutegravir. Aids. 2019;33(10):1663–8.
Neesgaard B, Mocroft A, Zangerle R, Wit F, Lampe F, Günthard HF, et al. Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS One. 2020;15(12 December):1–19.
Lübke N, Jensen B, Hüttig F, Feldt T, Walker A, Thielen A, Däumer M, Obermeier M, Kaiser R, Knops E, Heger E, Sierra S, Oette M, Lengauer T, Timm J HD. Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R. N Engl J Med. 2019;381(9):885–7.
McGee KS, Okeke NL, Hurt CB, McKellar MS. Canary in the coal mine? Transmitted mutations conferring resistance to all integrase strand transfer inhibitors in a treatment-naive patient. Open Forum Infect Dis. 2018;5(11):2016–8.
Fulcher JA, Du Y, Zhang TH, Sun R, Landovitz RJ. Emergence of Integrase Resistance Mutations during Initial Therapy Containing Dolutegravir. Clin Infect Dis. 2018;67(5):791–4.
Stekler JD, McKernan J, Milne R, Tapia KA, Mykhalchenko K, Holte S, et al. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther. 2015;20(1):77–80.
Brites C, Pinto-Neto L, Medeiros M, Nunes E, Sprinz E, Carvalho M. Extensive variation in drug-resistance mutational profile of Brazilian patients failing antiretroviral therapy in five large Brazilian cities. Brazilian J Infect Dis [Internet]. 2016;20(4):323–9. Available from: http://dx.doi.org/10.1016/j.bjid.2016.03.010
